INTRODUCTION {#s1}
============

Head and neck cancers (HNC) continues to be an important public health problem, with an estimated 700,000 new cases around the world in 2012 \[[@R1]\]. HNC includes a variety of cancers originating from different sites within the head and neck region, such as the oral cavity, oropharynx, hypopharynx and larynx. It is well documented that tobacco consumption and excessive alcohol drinking are independent major risk factors for the development of HNC \[[@R2]--[@R4]\]. Other possible risk factors include infection with human papilloma virus (HPV), poor oral hygiene, environmental carcinogens and genetic susceptibility \[[@R5]--[@R9]\]. Despite great advance in multidisciplinary treatment, approximately 30 - 50% patients with HNC survive over 5 years after initial diagnosis, and 15% - 20% patients will develop second primary malignancies after extensive therapy \[[@R10], [@R11]\]. Therefore, it is crucial that identifying potential chemopreventive measures other than tobacco and alcohol cessation should be further investigated.

Convincing laboratory evidence has emerged to demonstrate an association between chronic inflammation and cancer, which makes the anti-inflammatory drugs have emerged as the most potential chemopreventive agents \[[@R12]--[@R15]\]. Nonsteroidal anti-inflammatory drugs (NSAIDs), have received increasing attention because of their inhibitive effect on the cyclo-oxygenase (COX) enzymes, which may prevent synthesis of prostaglandins that stimulate growth and play a role in promoting carcinogenesis \[[@R16]--[@R19]\].

Several epidemiologic studies have observed use of aspirin and other NSAIDs have an association with reduced risk for cancers of the colon, stomach, prostate and breast \[[@R17], [@R20]--[@R22]\]. Even though some studies supported NSAIDs use significantly decrease the risk of HNC \[[@R11], [@R23], [@R24]\], while other studies did not show a consistent benefit \[[@R25], [@R26]\]. On the basis of the previous systematic review by Wilson et al. in 2011 \[[@R27]\], no definitive conclusion can be reached on NSAID/aspirin use and HNC risk. In addition, no meta-analysis and quantitative analysis was conducted due to the limited case number and heterogeneity of the studies identified. The purpose of the present study was to summarize all available evidence on this issue using a meta-analysis of observational studies.

RESULTS {#s2}
=======

Eligible studies {#s2_1}
----------------

The overview of our search process was illustrated in Figure [1](#F1){ref-type="fig"}. Eleven studies met the predetermined criteria for inclusion, with three cohort studies \[[@R24], [@R28], [@R29]\], and eight case-control studies \[[@R11], [@R23], [@R25], [@R26], [@R30]--[@R33]\]. The number of HNC cases ranged from 71 to 2,745 in the case-control studies, and from 68 to 185 in the cohort studies. Three studies were conducted in the United States \[[@R11], [@R24], [@R31]\], two in Denmark \[[@R28], [@R29]\], two in United Kingdom \[[@R26], [@R32]\], two in Italy \[[@R23], [@R33]\], one in Sweden \[[@R30]\] and the other one was coordinated by the International Agency for Research on Cancer (IARC) in fourteen European centers (in ten countries) \[[@R25]\]. These eleven studies were published between 2003 and 2015. The range of enrollment periods for participants across studies was 1982-2013. Table [1](#T1){ref-type="table"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"} listed the study characteristics and corresponding estimated OR with 95%CIs.

![The flow diagram of search strategy](oncotarget-07-65196-g001){#F1}

###### Characteristics of studies included in the meta-analysis of NSAIDs use and the risk of HNC

  Study                     Study design   Study location                                                                 Period                                               HNC sites                                                 Cases   Controls or cohort size   Type of drugs                                                  OR (95%CI)                                                Adjustment for covariates
  ------------------------- -------------- ------------------------------------------------------------------------------ ---------------------------------------------------- --------------------------------------------------------- ------- ------------------------- -------------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Bosetti et al, 2003       Case-control   Italy                                                                          1992 - 2000                                          Combined sites (oral, pharynx and larynx)                 965     1779                      Aspirin (at least once a week for more than 6 months)          0.86 (0.46 − 1.61)[^a^](#tfn_001){ref-type="table-fn"}    Age, gender, centre, educational, smoking, alcohol drinking
  935                       1732           Long-term aspirin use (duration of use ≧ 5 years)                              0.33 (0.13 − 0.82)                                                                                                                                                                                                                                                        
  Friis et al, 2003         Cohort         Denmark                                                                        1989 - 1995                                          Combined sites                                            68      29470                     Aspirin (75, 100 or 150 mg)                                    1.36 (1.04 − 1.77)[^b^](#tfn_002){ref-type="table-fn"}    Age, gender
  Oral and oropharynx       48             1.30 (0.90 − 1.70)                                                                                                                                                                                                                                                                                                                                       
  Larynx                    20             1.50 (0.90 − 2.40)                                                                                                                                                                                                                                                                                                                                       
  Rosenquist et al, 2005    Case-control   Sweden                                                                         2000 - 2004                                          Oral and oropharynx                                       132     320                       Aspirin (75-150 mg/day)                                        1.00 (0.60 − 1.70)[^a^](#tfn_001){ref-type="table-fn"}    Smoking, alcohol drinking
  Friis et al, 2006         Cohort         Denmark                                                                        1991 - 2002                                          Oral (month and tongue)                                   185     169589                    NA-NSAIDs (≧ 2 prescriptions)                                  1.20 (1.00 − 1.60)                                        Age, gender
  Jayaprakash et al, 2006   Case-control   United States                                                                  1982 - 1998                                          Combined sites                                            529     529                       Aspirin (ever used)                                            0.75 (0.58 − 0.96)                                        Age, gender, smoking, alcohol drinking
  Oral cavity               169            169                                                                            0.73 (0.51 − 1.05)                                                                                                                                                                                                                                                        
  Nasopharynx               22             22                                                                             0.88 (0.36 − 2.15)                                                                                                                                                                                                                                                        
  Oropharynx                102            102                                                                            0.68 (0.44 − 1.05)                                                                                                                                                                                                                                                        
  Larynx                    141            141                                                                            0.89 (0.58 − 1.35)                                                                                                                                                                                                                                                        
  Hypopharynx               31             31                                                                             0.77 (0.35 − 1.66)                                                                                                                                                                                                                                                        
  Combined sites            313            289                                                                            Long-term aspirin use (duration of use ≧ 10 years)   0.65 (0.52 − 0.82)[^c^](#tfn_003){ref-type="table-fn"}                                                                                                                                                               
  Ahmadi et al, 2010        Case-control   United States                                                                  2003 - 2007                                          Combined sites                                            71      71                        Any NSAIDs (ever used)                                         0.31 (0.11 − 0.88)                                        Educational, marital status
  44                        47             Any NSAIDs (daily)                                                             0.14 (0.04 −0.54)                                                                                                                                                                                                                                                         
  25                        25             Aspirin (daily)                                                                0.15 (0.02 − 1.30)                                                                                                                                                                                                                                                        
  Macfarlane et al, 2012    Case-control   European                                                                       NR                                                   Combined sites                                            1779    1993                      Aspirin (at least once a week for one year)                    0.92 (0.78 − 1.09) [^b^](#tfn_002){ref-type="table-fn"}   Age, gender, BMI, educational, smoking, alcohol drinking, fruit consumption
  Oral cavity               510            1993                                                                           1.04 (0.76 − 1.41)                                                                                                                                                                                                                                                        
  Oropharynx                474            1993                                                                           1.05 (0.76 − 1.46)                                                                                                                                                                                                                                                        
  OP NOS                    112            1993                                                                           1.29 (0.70 − 2.35)                                                                                                                                                                                                                                                        
  Larynx                    670            1993                                                                           0.74 (0.54 − 1.01)                                                                                                                                                                                                                                                        
  Hypopharynx               183            1993                                                                           0.53 (0.28 − 1.02)                                                                                                                                                                                                                                                        
  Combined sites            1588           1736                                                                           Long-term aspirin use (duration of use ≧ 5 years)    0.78 (0.58 − 1.05) [^d^](#tfn_004){ref-type="table-fn"}                                                                                                                                                              
  Wilson et al, 2013        Cohort         United States                                                                  1993 - 2001                                          Combined sites                                            316     141718                    Aspirin (regular use)                                          0.78 (0.62 − 0.98)                                        Age, gender, BMI, smoking
  315                       141550         Aspirin (daily)                                                                0.85 (0.65 − 1.11)                                                                                                                                                                                                                                                        
  316                       141718         Ibuprofen (regular use)                                                        0.97 (0.75 − 1.27)                                   Age, gender, BMI, smoking, aspirin use                                                                                                                                                                               
  Macfarlane et al, 2014    Case-control   United Kingdom                                                                 1996 - 2010                                          Combined sites                                            2392    7165                      Aspirin (≧ 1 prescriptions)                                    0.93 (0.76 − 1.15)                                        Age, gender, carstairs deprivation category, coronary heart disease, stroke
  2034                      6094           Long-term aspirin use (time between last and first prescription ≧ 5.4 years)   0.85 (0.70 − 1.04)                                                                                                                                                                                                                                                        
  2392                      7165           NA-NSAIDs (≧ 1 prescriptions)                                                  0.82 (0.70 − 0.96)                                                                                                                                                                                                                                                        
  Becker et al, 2015        Case-control   United Kingdom                                                                 1995 - 2013                                          Combined sites                                            2238    13488                     Aspirin (≧ 50 prescriptions)                                   1.21 (0.97 − 1.51)                                        BMI, smoking, alcohol drinking
  1932                      11657          Ibuprofen (≧ 6 prescriptions)                                                  0.78 (0.64 − 0.96)                                                                                                                                                                                                                                                        
  Di Maso et al, 2015       Case-control   Italy                                                                          1992 -2008                                           Nasopharynx                                               198     592                       Aspirin (at least one aspirin a week for more than 6 months)   0.24 (0.07 −0.87)                                         Age, gender, area of residence, smoking, period of interview, years of education, occupation

Abbreviations: BMI, body mass index; CI, confidence interval; F, female; HNC, Head and Neck Cancers; M, male; NR, not reported; NA-NSAIDs, non-aspirin nonsteroidal anti-inflammatory drugs; NSAIDs, nonsteroidal anti-inflammatory drugs; OP NOS, Oral, pharynx not otherwise specified; OR, odds ratio.

Cited from a systematic review by Wilson et al.;

Pooled from all cancer sites except for esophagus;

Pooled from the ORs of 10-20 years, 21-40 years and ≧40 years;

Pooled from the ORs of 5-9 years and ≧10years.

Quality of study methodologies {#s2_2}
------------------------------

Table [2](#T2){ref-type="table"} showed the quality of study methodology included in the meta-analysis. The range of quality scores was 5 - 8; the average score was 6.7. The average scores of cohort studies and case--control studies were 7.7 and 6.4, respectively, which suggests a reasonable good quality of the cohort and case--control studies.

###### Methodological quality of included studies based on the Newcastle--Ottawa Scale

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort studies (n=3)   Representa-tiveness of the exposed cohort   Selection\                Ascertainment of exposure   Outcome of interest not present at start of study   Control for Important factor or additional factor   Assessment of outcome   Follow-up long enough for outcomes to occur [^a^](#tfn_005){ref-type="table-fn"}   Adequacy of follow-up of cohorts   Total (0-9)
                                                                     of the unexposed cohort                                                                                                                                                                                                                                                                                     
  ---------------------- ------------------------------------------- ------------------------- --------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------- ---------------------------------------------------------------------------------- ---------------------------------- -------------
  Friis et al, 2003      ★                                           ★                         ★                           ★                                                   ★                                                   ★                       ★                                                                                  ★                                  8

  Friis et al, 2006      ★                                           ★                         ★                           ★                                                   ★                                                   ★                       ★                                                                                  ★                                  8

  Wilson et al, 2013     ★                                           ★                         \-                          ★                                                   ★                                                   ★                       ★                                                                                  ★                                  7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  Case-control studies (n=7)   Adequate definition of cases   Representa-tiveness of cases   Selection of contros   Definition of controls   Control for important factor or additional factor   Ascertainment of exposure   Same method of ascertainment for subjects   Nonresponse Rate [^b^](#tfn_006){ref-type="table-fn"}   Total (0-9)
  ---------------------------- ------------------------------ ------------------------------ ---------------------- ------------------------ --------------------------------------------------- --------------------------- ------------------------------------------- ------------------------------------------------------- -------------
  Bosetti et al, 2003          \-                             ★                              ★                      ★                        ★★                                                  \-                          ★                                           \-                                                      6
  Rosenquist et al, 2005       ★                              ★                              ★                      ★                        ★                                                   \-                          ★                                           \-                                                      6
  Jayaprakash et al, 2006      ★                              ★                              ★                      ★                        ★★                                                  \-                          ★                                           \-                                                      7
  Ahmadi et al, 2010           ★                              ★                              ★                      ★                        \-                                                  \-                          ★                                           \-                                                      5
  Macfarlane et al, 2012       ★                              ★                              ★                      ★                        ★★                                                  \-                          ★                                           \-                                                      7
  Macfarlane et al, 2014       ★                              ★                              ★                      ★                        ★                                                   ★                           ★                                           \-                                                      7
  Becker et al, 2015           ★                              ★                              ★                      ★                        ★                                                   ★                           ★                                           \-                                                      7
  Di Maso et al, 2015          ★                              ★                              \-                     ★                        ★                                                   \-                          ★                                           ★                                                       6

A cohort study with a follow-up time \> 5 years was assigned one star;

Same rate for both groups was assigned one star.

Overall use of NSAIDs and the risk for HNC {#s2_3}
------------------------------------------

Figure [2](#F2){ref-type="fig"} illustrated the forest plot of ORs estimates with 95%CIs from individual studies and overall meta-analysis of all eleven studies \[[@R11], [@R23]-[@R26], [@R28]-[@R33]\]. The overall summary ORs demonstrated no significant association between overall NSAIDs use and the risk of HNC (OR=0.95; 95%CI, 0.81-1.11), with statistical heterogeneity among studies (*P*=0.001; *I^2^*=67.4%). The tests for funnel plot asymmetry by Begg\'s test and Egger\'s test identified no publication bias (Begg\'s test, *P* = 0.276; Egger\'s test, *P* = 0.229).

![Forest plots of meta-analysis of overall NSAIDs use and the risk of HNC](oncotarget-07-65196-g002){#F2}

Subgroup analyses {#s2_4}
-----------------

Table [3](#T3){ref-type="table"} showed the associations between NSAIDs use and the risk of HNC in subgroup meta-analyses by various factors. The subgroup analyses were conducted on the basis of different types of NSAIDs use. There was no significant association between use of aspirin \[[@R11], [@R23]--[@R26], [@R28], [@R30]--[@R33]\] or non-aspirin nonsteroidal anti-inflammatory drugs (NA-NSAIDs) \[[@R24], [@R26], [@R29], [@R32]\] and the risk of HNC, with OR of 0.93 (95%CI, 0.79-1.10) and OR of 0.92 (95%CI, 0.76-1.10), respectively. For the two studies evaluated exposure to ibuprofen and the risk of HNC \[[@R24], [@R32]\], a significant protective effect was observed (OR = 0.85; 95%CI, 0.72-0.99). We also found long- term usage of aspirin (≧5 years) has been associated with a significant 25% reduction in HNC risk from four studies \[[@R11], [@R23], [@R25], [@R26]\] (OR=0.75; 95%CI, 0.65-0.85) (Figure [3](#F3){ref-type="fig"}), and statistical heterogeneity was not detected.

![Forest plots of meta-analysis of long-term usage of aspirin and the risk of HNC](oncotarget-07-65196-g003){#F3}

###### Associations between NSAIDs use and the risk of HNC in subgroup meta-analyses

  Studies groups                No. of Studies   Summary OR (95% CI)   Homogeneity   Model used   Publication Bias           
  ----------------------------- ---------------- --------------------- ------------- ------------ ------------------ ------- -------
  **Type of drugs use**                                                                                                      
   Aspirin                      10               0.93 (0.79 − 1.10)    0.002         65.0%        Random-effects     0.474   0.255
   NA-NSAIDs                    4                0.92 (0.76 − 1.10)    0.026         67.7%        Random-effects     0.734   0.342
   Ibuprofen                    2                0.85 (0.72 − 0.99)    0.199         39.5%        Fixed-effects      1.000   NA
  **Long-term aspirin use**     4                0.75 (0.65 − 0.85)    0.103         51.5%        Fixed-effects      0.308   0.313
  **HNC sites**                                                                                                              
   Oral and oropharynx          5                1.01 (0.85 − 1.20)    0.098         43.9%        Random-effects     0.230   0.139
   Larynx                       3                0.96 (0.65 − 1.42)    0.059         64.7%        Random-effects     0.296   0.253
   Hypopharynx                  2                0.62 (0.38 − 1.01)    0.469         0.0%         Fixed-effects      1.000   NA
   Nasopharynx                  2                0.50 (0.14 − 1.76)    0.099         63.2%        Random-effects     1.000   NA
  **Study design**                                                                                                           
   Case-control                 8                0.89 (0.74 − 1.07)    0.017         59.1%        Random-effects     0.108   0.130
   Cohort                       3                1.08 (0.77 − 1.51)    0.003         82.4%        Random-effects     0.296   0.446
  **Sample sizes**                                                                                                           
   ≧ 1000                       8                0.99 (0.85 − 1.15)    0.003         67.1%        Random-effects     0.711   0.897
   \< 1000                      3                0.47 (0.18 − 1.27)    0.031         71.1%        Random-effects     0.296   0.059
  **Exposure source**                                                                                                        
   Questionnaire                6                0.82 (0.73 − 0.92)    0.090         47.5%        Random-effects     0.060   0.040
   Prescription database        4                1.14(1.02 -- 1.28)    0.118         48.9%        Fixed-effects      0.308   0.134
  **Adjustments for age**                                                                                                    
   Yes                          8                0.93 (0.79 − 1.11)    0.003         68.0%        Random-effects     0.711   0.478
   No                           3                0.89 (0.51 −1.53)     0.039         69.3%        Random-effects     0.296   0.233
  **Adjustments for gender**                                                                                                 
   Yes                          8                0.93 (0.79 − 1.11)    0.003         68.0%        Random-effects     0.711   0.478
   No                           3                0.89 (0.51 −1.53)     0.039         69.3%        Random-effects     0.296   0.233
  **Adjustments for smoking**                                                                                                
   Yes                          7                0.88 (0.73 − 1.06)    0.022         59.6%        Random-effects     0.230   0.382
   No                           4                1.05 (0.78 − 1.40)    0.011         73.2%        Random-effects     1.000   0.454
  **Adjustments for alcohol**                                                                                                
   Yes                          5                0.95 (0.79 −1.14)     0.083         51.5%        Random-effects     1.000   0.908
   No                           6                0.91 (0.69 −1.21)     \<0.001       77.5%        Random-effects     1.000   0.229
  **Adjustments for BMI**                                                                                                    
   Yes                          3                0.95 (0.76 − 1.20)    0.023         73.6%        Random-effects     1.000   0.939
   No                           8                0.92 (0.72 − 1.17)    0.002         69.4%        Random-effects     0.386   0.164

Abbreviations: BMI, body mass index; CI, confidence interval; HNC, Head and Neck Cancers; NA, not available; NA-NSAIDs, non-aspirin nonsteroidal anti-inflammatory drugs; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio.

There are six studies provided results on the effect of NSAIDs for specific HNC sites. However, NSAIDs use was not associated with a reduced risk for cancer of oral and oropharynx \[[@R11], [@R25], [@R28]--[@R30]\] (OR=1.01; 95%CI, 0.85 − 1.20), larynx \[[@R11], [@R25], [@R28]\] (OR=0.96; 95%CI, 0.65- 1.42), hypopharynx \[[@R11], [@R25]\] (OR=0.62; 95%CI, 0.38 − 1.01) and nasopharynx \[[@R11], [@R33]\] (OR=0.50; 95%CI, 0.14 − 1.76).

To examine consistency across varying study designs with different potential biases, we stratified data into subgroups on the basis of study design. The summary ORs were 0.89 (95%CI: 0.74 − 1.07) pooled from eight case-control studies \[[@R11], [@R23], [@R25], [@R26], [@R30]--[@R33]\] and 1.08 (95%CI: 0.77 − 1.51) across three cohort studies \[[@R24], [@R28], [@R29]\].

The impact of sample size on risk estimates was assessed. The summary ORs were 0.99 (95%CI: 0.85 − 1.15) in eight studies \[[@R11], [@R23]--[@R26], [@R28]--[@R32]\] with relatively large sample size (≧1,000) and 0.47 (95% CI: 0.18 − 1.27) from the other three studies with the sample size less than 1,000 \[[@R30], [@R31], [@R33]\].

Recorded prescription database, self-administered questionnaires and standardized interviews were used to obtain information on NSAIDs exposure. The summary ORs were 0.82 (95%CI: 0.73 − 0.92) pooled from six questionnaire-based studies \[[@R11], [@R23]--[@R25], [@R31], [@R33]\] and 1.14 (95%CI: 1.02 − 1.28) from four studies based on prescription \[[@R26], [@R28], [@R29], [@R32]\]. These results suggested a significant protective effect was observed only in studies based on questionnaire.

In subgroup analyses by varied adjustment factors including age, gender, smoking, alcohol drink and body mass index (BMI), the association between NSAIDs use and the risk of HNC were non-significant in all strata (Table [2](#T2){ref-type="table"}).

DISCUSSION {#s3}
==========

The findings from this meta-analysis of eleven observational studies, including 370,000 participants and 10,673 HNC cases, did not indicate overall NSAIDs use was significantly associated with a decreased risk for HNC.

When stratified by type of drugs, there was no association between use of aspirin or NA-NSAIDs and the risk of HNC. However, we observed a significant risk reduction of 15% in HNC risk for users of ibuprofen alone (OR = 0.85; 95%CI, 0.72-0.99). It was suggested that different types of NSAIDs might have different effects due to biological mechanisms \[[@R34], [@R35]\]. Andrews et al. had demonstrated that ibuprofen was more effective at reducing cancer cell growth and survival across a variety of cancer cell lines compared to other NSAIDs \[[@R36], [@R37]\], which may explain our findings.

It is widely accepted that any potential protective effects of NSAIDs use against cancers are likely to involve a considerable duration \[[@R38]\]. Previous large randomized trials and cohort studies showed long-term use of aspirin and other NSAIDs have almost consistently been associated with a stronger reduced risk of colorectal cancer \[[@R39]--[@R41]\]. The time-risk relations are similar to those described for colorectal cancer, our results also observed a significant association between long-term aspirin use and the risk of HNC (OR=0.78; 95%CI, 0.67-0.92).

A significant preventive effect of NSAIDs use on HNC risk was observed in questionnaire-based studies but not in prescription-based studies. Studies that use prescription databases have their own shortcomings. Generally, no data were available regarding the use of over-the-counter medications including aspirin and NSAIDs, which will have underestimated exposure to these drugs. However, results from questionnaire-based studies should be interpreted cautiously for recall bias or selection bias. If the relatively healthy aspirin users were more likely to participate in the study than non-users, and an overestimate inverse association could be observed.

The previous systematic review including 2 cohort studies \[[@R28], [@R29]\] and 3 case-control studies \[[@R11], [@R23], [@R30]\], conducted by Wilson et al. also suggested no definitive conclusion can be reached on the preventive effect of NSAIDs on HNC risk \[[@R27]\]. The strengths of our meta-analysis were as follows: First, our present study included sufficient cases and quantitatively analyzed the effect of NSAIDs/aspirin using a detailed meta-analysis of eleven observational studies; Second, we were more capable to investigate potentially different effects on risk by the type and duration of NSAIDs use. As mentioned in the conclusion of Wilson\'s systematic review, aspirin may protect against HNC. We not only found a significant risk reduction in HNC risk for long-term aspirin but also ibuprofen user; Third, we performed the publication bias and more subgroup analyses, which reinforce our confidence in the validity of the conclusion.

There were some potential limitations that have to be considered when interpreting these results. First, this meta-analysis is based on observational studies, which are more susceptible to recall and selection biases, and could result in an underestimation or an overestimation of the true effect. However, It may be unfeasible to evaluate the long-term protective effects of NSAID from randomized clinical trials due to the large sample size required; Second, we did not take into account possible interactions with other drugs due to absence of data. Use of NSAIDs are often associated with other drugs use, which could have concealed a possible association with NSAIDs \[[@R42]\]. Third, none of the studies included adjusted the analyses for HPV infection, which has been shown to have an etiological role in HNC as well as smoking and heavy alcohol drink, and there was some evidence to suggest an up-regulation of COX-2 in HPV-infected tissues \[[@R43], [@R44]\]. Fourth, HNC are a heterogeneous group of neoplasms, and we conducted subgroup analyses separately for specific HNC sites, however no significant risk reduction was found; Fifth, the possibility of publication bias is always a concern in meta-analyses of published studies. This could bias the results of this review if negative studies were less likely to be published. In our meta-analysis, a significant publication bias in the subgroup of long-term aspirin use was observed from the Egger\'s test (P=0.055) but not the Begg\'s test (P=0.308). We consider the discrepancy was due to the small number of studies included.

In conclusion, our meta-analysis does not support the hypothesis that overall use of NSAIDs significant reduces the risk of HNC. Whereas, we cannot rule out a modest reduction in HNC risk associated with ibuprofen and long-term aspirin use. Further large-scale robust studies are required, in particular, those evaluating the duration of aspirin use that may be take a protective effect.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

This meta-analysis was conducted according to the meta-analysis of Observational Studies in Epidemiology (MOOSE) Guidelines \[[@R45]\]. We systematically searched Pubmed, Embase, Google scholar, and Cochrane library for manuscripts that mentioned the relationship between the use of aspirin and NSAIDs and the risk of HNC without language restriction, from January 1980 to April 2016. Our search terms consisted of three main components, head and neck (head and neck OR oral OR oropharynx OR hypopharynx OR larynx OR upper aerodigestive tract) AND disease (cancer OR neoplasms OR carcinoma) AND the exposure factor (aspirin OR NSAIDs OR ibuprofen OR naproxen OR indomethacin OR meloxicam OR valdecoxib OR celecoxib OR rofecoxib). We also reviewed the reference lists of articles with information on the topic to retrieve additional pertinent studies. If necessary, we attempted to contact the authors if we required additional information.

Study selection {#s4_2}
---------------

Studies that met the following criteria were eligible for inclusion: (1) use a case--control or cohort study design; (2) evaluate the association between NSAIDs use and the risk of HNC; (3) provided the odds ratio (OR) or relative risk (RR) with corresponding confidence interval (CI) or sufficient data to calculate them. When the same author reported results obtained from the same population in more than one publication, only the most recent report, or the most complete one, was included in the analysis. Data from review articles, case reports, abstracts, and letters were not included.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two investigators (Lanhua Tang and Huabin Hu) extracted the following information from each eligible studies independently: the last name of the first author, year of publication, study design, country where the study was performed, enrollment periods, HNC sites, sample size (numbers of case patients and control subjects), types of NSAIDs use, the source of NSAIDs exposure information, the source of HNC diagnosis, the ORs or RRs with corresponding 95%CI and adjustment for covariates. Differences in data extraction were resolved by consensus, referring back to the original article.

The methodological quality of the included studies was assessed using the 9-star Newcastle--Ottawa scale for quality of nonrandomized studies in meta-analyses \[[@R46]\]. The Newcastle-Ottawa Scale consists of eight items, which are categorized three categories: selection (one star each), comparability (up to two stars), and exposure/outcome (one star each). A "star" presents a "high-quality" choice of individual study.

Statistical analysis {#s4_4}
--------------------

Odds ratio (OR) was used as a measure of the association between use of NSAIDs and risk of HNC. Because the absolute risk of HNC is low, the OR in case--control studies was considered reasonable approximations of the corresponding rate ratios in cohort studies \[[@R47]\]. The heterogeneity of the estimators of OR was tested by Cochran\'s Q test at the *P* \<0.10 level of significance \[[@R48]\]. We also calculated the quantity *I*^2^ that describes the percentage variation across studies that is attributed to heterogeneity \[[@R49], [@R50]\]. When significant heterogeneity was found, the random-effects model with the DerSimonian-Laird method was used for meta-analysis \[[@R51]\]. Otherwise, the fixed-effects model with Mantel--Haenszel method was adopted \[[@R52]\]. Publication bias was evaluated using the Begg\'s adjusted rank correlation test \[[@R53]\], and the Egger\'s regression asymmetry test \[[@R54]\]. *P* \<0.10 was considered to represent statistically significant publication bias.

When study reported results separately for aspirin and non-aspirin NSAIDs (NA-NSAIDs), to avoid double counting of the cases, we included only the results for aspirin in the overall summary estimate. Use of NSAIDs has the definition as follows:"overall use" was all the reported intake levels of NSAIDs use,"long-term use" was defined the duration of NSAIDs use or the time between last and first prescription more than 5 years. We only calculated the results for combined sites of HNC in the overall estimate, if studies had results for specific site and combined sites of HNC.

Analysis was performed using the STATA version 11.0 (Stata Corporation, College Station, Texas).
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===================
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